Adcetris (brentuximab vedotin) / Takeda, Pfizer - LARVOL DELTA

Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial. (PubMed, Lancet) - P3 | "BrECADD guided by PET after two cycles is better tolerated and more effective than eBEACOPP in first-line treatment of adult patients with advanced-stage, classical Hodgkin lymphoma."

Journal • Metastases • P3 data • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

Final results of a multicentre pilot study evaluating brentuximab vedotin with cyclophosphamide, doxorubicin, etoposide and prednisone (BV-CHEP) for the treatment of aggressive adult T-cell leukaemia/lymphoma. (PubMed, Br J Haematol) - No abstract available

Journal • Adult T-Cell Leukemia-Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma

Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826. (PubMed, J Clin Oncol) - "Patient-reported outcomes of key adverse events confirmed the improved toxicity profile of N-AVD over BV-AVD. N-AVD was better tolerated and more effective than BV-AVD and is therefore a new standard of care for older patients with advanced-stage cHL fit for anthracycline-based combination therapy."

Journal • Classical Hodgkin Lymphoma • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Infectious Disease • Lymphoma • Neutropenia • Oncology • Pain • Septic Shock

Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-up. (PubMed, Blood Cancer J) - P3 | "ClinicalTrials.gov number: NCT01777152."

Journal • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Systemic Anaplastic Large Cell Lymphoma

Clinical prognostication in the SWOG 1826 randomized clinical trial of nivolumab-AVD versus brentuximab-AVD: Performance of the advanced-stage Hodgkin lymphoma international prognostic index (A-HIPI) (ASH 2025) - "The phase 3 randomized SWOG S1826 study, the largest National Clinical Trials Network study of AS cHL,compared nivolumab with doxorubicin, vinblastine, and dacarbazine (N+AVD) with brentuximab vedotinwith doxorubicin, vinblastine, and dacarbazine (BV+AVD) in pts 12 yrs or older with AS newly diagnosedcHL. This refined prediction model, which leverages continuous datavalues, is poised to serve as the new standard for risk stratification for adults with AS cHL. Funding NIH/NCI grant awards U10CA180888, U10CA180819, R01CA262265-04"

Clinical • Metastases • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma

Final analysis of the Phase III GHSG HD21 trial: PET-guided brecadd vs. ebeacopp in advanced-stage classical Hodgkin lymphoma (ASH 2025) - P3 | "Introduction The German Hodgkin Study Group (GHSG) HD21 trial for adult patients with newly diagnosed advanced-stage classical Hodgkin lymphoma (AS-cHL) was designed to reduce treatment-related morbidity (TRMB)and improve efficacy by comparing the novel BrECADD regimen (brentuximab vedotin, etoposide,cyclophosphamide, doxorubicin, dacarbazine, dexamethasone) to the standard eBEACOPP protocol.Here, we report the final efficacy and safety including long-term progression-free survival (PFS), overallsurvival (OS), and late toxicity outcomes. While higher baseline lymphoma burden associates with incomplete remission atPET2, the risk for treatment failure seems mitigated through response-adaptation. Taken together, ourresults establish individualized BrECADD as a standard treatment option for adult patients with newlydiagnosed AS-cHL."

Metastases • P3 data • Acute Myelogenous Leukemia • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma

Circulating tumor DNA analyses of molecular tumor burden are superior to PET-assessed responses in patients with advanced stage classic Hodgkin lymphoma treated on SWOG S1826 (ASH 2025) - "In the S1826 phase III trial, patients (pts) with newlydiagnosed advanced stage cHL who were treated with nivolumab (N)-AVD, vs brentuximab-vedotin (BV)-AVD, had improved progression-free survivals (PFS), establishing a new standard of care. In S1826, ctDNA-guided analyses of MTB enabled early risk stratification at C3D1 andstrongly outperformed PET assessments at EOT. Future prospective studies should incorporate ctDNAanalyses of MTB to improve precision therapy in cHL."

Circulating tumor DNA • Clinical • IO biomarker • Metastases • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

Effects of antibiotic prophylaxis in first-line therapy of advanced stage classic Hodgkin lymphoma: An analysis of the GHSG HD21 study (ASH 2025) - "In the GHSG HD21 trial for advanced-stage classic Hodgkin lymphoma (AS-cHL), patients received polychemotherapy regimens (eBEACOPP[bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone] orBrECADD [brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, anddexamethasone]) with a risk to develop febrile neutropenia (FN) and/or infections. This comprehensive analysis of the HD21 trial demonstrates the efficacy of ABP and peg G-CSF in thetreatment of AS-cHL in preventing FN and higher-grade infections. This effect is most pronounced in thefirst cycle and in patients receiving BrECADD. Based on these results, we recommend the use of ABPduring the first cycle of the BrECADD regimen, at least."

Clinical • Metastases • Classical Hodgkin Lymphoma • Febrile Neutropenia • Hematological Malignancies • Hodgkin Lymphoma • Infectious Disease • Lymphoma • Neutropenia

Brentuximab Vedotin and Nivolumab in Combination With Chemotherapy for Nonbulky, Early-Stage Classical Hodgkin Lymphoma. (PubMed, Blood) - P2 | "Most patients with early-stage classical Hodgkin lymphoma (cHL) are treated with doxorubicin, bleomycin, vinblastine, and dacarbazine with or without radiation therapy, although studies are now evaluating the incorporation of novel agents paired with abbreviated chemotherapy. Results from this study support the use of BV and nivolumab in combination with limited chemotherapy in patients with non-bulky, early-stage cHL. ClinicalTrials.gov: NCT03646123."

Journal • Classical Hodgkin Lymphoma • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Neutropenia • Oncology

Novel agents and therapeutic advances in T cell lymphoma. (PubMed, Int J Hematol) - "CHOP or CHOP-like regimens have long been the standard frontline therapy; however, the addition of brentuximab vedotin has improved overall survival and established a new standard of care for CD30-positive PTCL...Epigenetic modulators, including histone deacetylase inhibitors and an EZH1/2 inhibitor, have demonstrated particularly high activity in TFH-derived subtypes, supporting the integration of biomarker-driven patient selection as a path toward precision medicine in PTCL. This review summarizes current insights into the genetic landscape, recent clinical advances in novel agents, and future perspectives on therapeutic stratification, highlighting the need to translate molecular insights into durable clinical benefits for patients with PTCL."

Journal • Review • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • EZH2 • GATA3 • TBX21 • TNFRSF8

Brentuximab Vedotin (BV) in Combination With Lenalidomide (Len) and Rituximab (R) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Results From the Phase 3 ECHELON-3 Study (SOHO 2024) - P3 | "Compared with R2, BV+R2 demonstrated statistically significant and clinically meaningful OS improvements with a manageable safety profile. BV+R2 is a promising treatment option for patients with R/R DLBCL."

Clinical • Combination therapy • P3 data • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • TNFRSF8

Efficacy of 2nd-line treatment in CLL after venetoclax-based 1st-line treatment: Results from the GAIA/CLL13 trial (ASH 2025) - "We reportefficacy outcomes for 177 patients receiving 2nd-line treatment after prior reporting of progression in theGAIA/CLL13 trial.In the GAIA/CLL13 trial, 926 physically fit patients with CLL and without TP53 aberration were randomizedbetween 1st-line treatment with chemoimmunotherapy (CIT, n=229), rituximab-venetoclax (RV, n=237),obinutuzumab-venetoclax (GV, n=229), and GV-ibrutinib (GIV, n=231)...The 13 patients with progression as Richter's transformation received R-CHOP-like therapy(n=8), ABVD-like therapy (n=2), brentuximab, rituximab-venetoclax or allogeneic stem cell transplant (n=1each).For patients who had received CIT in 1st-line treatment, 1 received CIT again, 34 received BTK inhibitor-based, 22 received venetoclax-based, and 5 received venetoclax + BTK inhibitor therapy...The majority received acalabrutinib + venetoclax (AV, n=24); 2 received AV +obinutuzumab as 2nd-line treatment.The 2-year TFS2 rate was 21.4% for CIT, 76.6% for BTK inhibitor-based,..."

Clinical • Chronic Lymphocytic Leukemia • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Immunology • Leukemia • Rare Diseases • Richter's Syndrome • CD20 • TP53

Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Results from the phase 3 ECHELON-3 study. (ASCO 2024) - P3 | "Treatment with BV+R2 triplet, compared to R2, demonstrated statistically significant and clinically meaningful improvements in all key efficacy outcomes including OS in high-risk subgroups, with manageable safety. This triplet regimen represents a novel treatment option for pts with heavily pretreated R/R DLBCL."

Clinical • Combination therapy • Late-breaking abstract • P3 data • Anemia • Bone Marrow Transplantation • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Pain

Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas. (PubMed, Haematologica) - P1/2 | "In the PMBCL cohort, 2-year PFS was 86% (95% CI: 62-95). In summary, BV-R-CHP with or without consolidative radiation is a feasible and active frontline regimen for CD30+ B-cell lymphomas (NCT01994850)."

Clinical • Combination therapy • Journal • Diffuse Large B Cell Lymphoma • Lymphoma • Mediastinal B Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma. (PubMed, N Engl J Med) - P3 | "N+AVD resulted in longer progression-free survival than BV+AVD in adolescents and adults with stage III or IV advanced-stage classic Hodgkin's lymphoma and had a better side-effect profile. (Funded by the National Cancer Institute of the National Institutes of Health and others; S1826 ClinicalTrials.gov number, NCT03907488.)."

Clinical • Journal • Metastases • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology • Pediatrics

3-year follow-up of the S1826 study confirms improved progression-free survival with nivolumab-AVD compared to brentuximab vedotin-AVD in advanced stage classic Hodgkin lymphoma (ASH 2025) - "Introduction: The randomized phase 3 S1826 study demonstrated that, in adolescent and adult patients(pts) with previously untreated advanced stage (AS) classic Hodgkin lymphoma (cHL), PD-1 blockade withnivolumab in combination with doxorubicin, vinblastine, and dacarbazine (N-AVD) prolongedprogression-free survival (PFS) compared with standard brentuximab vedotin (BV) combined with AVD ata median follow-up of 2 years. The benefit of N-AVD compared to BV-AVD in adolescent and adult pts with AS cHL issustained with 3y follow-up, including all pre-specified age, stage, and IPS risk subgroups. This updatedemonstrates the durability of remissions with N-AVD over time without any new safety signals, andenables benchmarking with other modern cHL trials. Follow-up will continue to evaluate for latetoxicities, OS, and PROs."

Metastases • Classical Hodgkin Lymphoma • Genetic Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Skin Cancer • Solid Tumor

Safety and efficacy of MT-601 in relapsed or refractory (r/r) Hodgkin lymphoma (ASH 2025) - P1 | "HL pts received standard dosesof a lymphodepletion chemotherapy (LDC) regimen (Flu/Cy or bendamustine was allowed per protocol)for three consecutive days (Day -5 to Day -3) before infusion of MT-601 (MT-601 doses: 200 x106 cells n=3; 300 x106 cells n=2; 400 x106 cells n=4). Initial disease assessment was conducted 8 weeks post MT-601infusion.The 9 HL pts (female n=4; male n=5) had a median age of 43 (range 30-75) and had undergone a medianof 8 prior lines of therapy, with all 9 pts having received prior brentuximab, PD-1 and HSCT (autologousn=5; allogeneic n=2; autologous and allogeneic n=2)...These preliminary findings from the Phase 1 APOLLO study demonstrate that MT-601 has a favorablesafety profile and early objective responses in heavily pre-treated HL pts. The encouraging tolerability ina population with limited treatment options supports the potential of MT-601 to address a significantunmet medical need and warrants further clinical examination. We will..."

Clinical • IO biomarker • B Cell Lymphoma • Bone Marrow Transplantation • Hodgkin Lymphoma • Immunology • Lymphoma • Non-Hodgkin’s Lymphoma • Primary Immunodeficiency • BIRC5 • CTAG1B • MAGEA4 • PD-1 • PRAME • WT1

Hodgkin Lymphoma With Liver Involvement (Diagnostic, Therapeutic Difficulties, and Literature Review): A Retrospective Cohort Study. (PubMed, Health Sci Rep) - "PET/CT can be a practical tool to support diagnosis and monitor response to therapy in patients where liver biopsy is not possible or does not contribute significantly to clinical management. With preserved liver function, ABVD is an effective treatment option, while with worsening liver function, brentuximab vedotin can be a safe alternative."

Journal • Retrospective data • Classical Hodgkin Lymphoma • Hematological Malignancies • Hepatology • Hodgkin Lymphoma • Liver Failure • Lymphoma • Oncology

RESULTS FROM THE DOSE-FINDING PART OF LuminICE-203 PHASE 2 STUDY: ACIMTAMIG (AFM13) IN COMBINATION WITH AlloNK (AB-101) IN PATIENTS WITH RELAPSED/ REFRACTORY HODGKIN LYMPHOMA (ICML 2025) - P2 | "Introduction: New therapeutic options are needed for patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) who progress following standard systemic therapies including chemotherapy, brentuximab vedotin (BV), and checkpoint inhibitors. The combination of acimtamig and AlloNK has shown promising efficacy with a well-managed safety profile, indicating potential therapeutic benefits and offering hope for patients with R/R cHL who have exhausted standard-of-care treatment options."

Clinical • Combination therapy • P2 data • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology • FCGR3A • TNFRSF8

TISLELIZUMAB, AN ANTI-PD-1 ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA: FINAL ANALYSIS FROM THE LYSA PHASE 2 TIRHOL STUDY BGB-A317-210 (ICML 2025) - P2 | "The median prior lines of therapy received was 2 (1–4); 27% of pts received ≥ 3 prior lines of therapy and 73% received prior brentuximab vedotin. With a median follow-up of 30 mos, this study confirmed that tislelizumab is an effective therapeutic option for pts with R/R cHL, including those unfit for ASCT. Approximately 1/3 of the study population continued tislelizumab due to ongoing clinical benefit beyond SUV increase meeting PD criteria. The safety profile of tislelizumab remains acceptable, consistent with that of the PD-1 inhibitor class."

Clinical • P2 data • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma. (PubMed, N Engl J Med) - P3 | "Patients who received A+AVD for the treatment of stage III or IV Hodgkin's lymphoma had a survival advantage over those who received ABVD. (Funded by Takeda Development Center Americas and Seagen; ECHELON-1 ClinicalTrials.gov number, NCT01712490; EudraCT number, 2011-005450-60.)."

Journal • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Neutropenia • Oncology • Pain • Transplantation

Pembrolizumab and Involved Site Radiation Therapy Alone as an Alternative to Transplant in Patients with Localized Failure following Chemotherapy for Hodgkin Lymphoma: A Prospective Multicenter Phase II Study (ASTRO 2025) - "16 (89%) received doxorubicin/hydroxydaunorubicin, bleomycin, vinblastine, and dacarbazine (ABVD), 12 (67%) with <6 cycles...Subsequent treatment for the three patients currently in remission included pembro plus gemcitabine/vinorelbine/liposomal doxorubicin followed by ASCT (n=1), brentuximab vedotin (BV) plus nivolumab followed by ASCT (n=1) and 2 doses of BV followed by additional RT (n=1)... Pembro-RT yielded excellent CMR rates and minimal toxicity. These data suggest pembro-RT as a potential alternative to high dose chemo and SCT in localized, favorable relapsed/refractory HL. Enrollment to the study is complete and data will be updated prior to the meeting."

Clinical • P2 data • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

High efficacy and durability of second-line therapy with pembrolizumab gemcitabine vinorelbine and liposomal doxorubicin in the phase II study for relapsed and refractory Hodgkin lymphoma (ISHL 2022) - "36 pts proceeded to HDT/AHCT of whom 13 (36%) received post-transplant brentuximab vedotin (BV) (n=12) or BV plus nivolumab (bv/nivo) (n=1) maintenance. Second-line therapy with P-GVD is highly effective and efficiently bridges pts with RR cHL to HDT/AHCT. With extended follow-up for transplanted pts, remissions remain durable with estimated 30-month PFS of 96%. Among 68 evaluable pts enrolled onto parts I and II, CR rate remains high at 92.6%."

Clinical • P2 data • Anemia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Infectious Disease • Inflammation • Lymphoma • Mucositis • Neutropenia • Oncology • Pneumonia • Respiratory Diseases • Septic Shock • Transplantation

Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma. (PubMed, J Clin Oncol) - P2 | "Second-line therapy with pembro-GVD is a highly effective and well-tolerated regimen that can efficiently bridge patients with rel/ref cHL to HDT/AHCT."

Clinical • Journal • P2 data • Endocrine Disorders • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Mucositis • Neutropenia • Oncology • Transplantation • FDG PET

Phase 2 open-label study of brentuximab vedotin (BV) + pembrolizumab (pembro) in patients (pts) with treatment (tx)-naive metastatic head and neck squamous cell carcinoma (HNSCC). (ASCO 2025) - P2 | "BV + pembro demonstrated promising clinical efficacy with a safety profile consistent with each individual agent in pts with tx-naive metastatic HNSCC with PD-L1 CPS ≥1. Biomarker analyses support the hypothesized immunomodulatory mechanism of action of BV + pembro. These encouraging data are consistent with prior findings in PD-1–refractory NSCLC and melanoma and support continued investigation of CD30-directed ADCs + anti–PD-1 therapy in solid tumors."

Clinical • IO biomarker • Metastases • P2 data • Fatigue • Head and Neck Cancer • Hematological Disorders • Lung Cancer • Melanoma • Neutropenia • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck